Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Controlled Multicenter Surgical Trial to Evaluate the Impact of a Lymphoscintigraphy Prior to Sentinel Node Biopsy in Early Breast Cancer; SenSzi (GBG80)

NCT02481128 is registered in ClinicalTrials.gov with Kliniken Essen-Mitte as lead sponsor.

NCT NCT02481128
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02481128 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Controlled Multicenter Surgical Trial to Evaluate the Impact of a Lymphoscintigraphy Prior to Sentinel Node Biopsy in Early Breast Cancer; SenSzi (GBG80)
Lead sponsor
Kliniken Essen-Mitte
Phase
Not applicable
Overall status
Completed
Start date
May 31, 2014
Completion date
January 31, 2017
Enrollment
1,198 (actual)
Sites
23

Conditions

As the registry lists them; a condition with its own page is linked.

early-stage breast carcinoma